{"entity":{"type":"insider","cik":"0001703031","url":"/insider/0001703031","json_url":"/insider/0001703031.json","name":"Bain Capital Life Sciences Investors, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":30,"n_filings":20,"first":"2017-12-19","last":"2026-04-30","span_basis":"filed_date"},"name_variants":[{"name":"Bain Capital Life Sciences Investors, LLC","source":"filing","n_filings":20,"first_seen":"2017-12-19","last_seen":"2026-04-30"}],"transactions":[{"id":6017270,"accession":"0001193125-26-198593","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-198593","line_url":"/filing/0001193125-26-198593#line-4","is_derivative":false,"issuer_cik":"0001464521","issuer_name":"Heartflow, Inc.","issuer_ticker":"HTFL","issuer_name_source":null,"issuer_url":"/issuer/0001464521","owner_cik":null,"owner_name":"BCLS Fund III Investments GP, LLC; BCLS Fund III Investments, LP; Bain Capital Life Sciences Fund III, L.P.; Bain Capital Life Sciences III General Partner, LLC; Bain Capital Life Sciences Investors, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":892533.0,"shares_display":"892,533","price_per_share":29.18,"price_display":"29.18","price_state":"stated","total_value":26044112.94,"total_display":"26,044,112.94","shares_owned_after":8504382.0,"shares_owned_after_display":"8,504,382","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-30","filed_date":"2026-04-30","scope":"insider"},{"id":6017266,"accession":"0001193125-26-198593","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-198593","line_url":"/filing/0001193125-26-198593#line-3","is_derivative":false,"issuer_cik":"0001464521","issuer_name":"Heartflow, Inc.","issuer_ticker":"HTFL","issuer_name_source":null,"issuer_url":"/issuer/0001464521","owner_cik":null,"owner_name":"BCLS Fund III Investments GP, LLC; BCLS Fund III Investments, LP; Bain Capital Life Sciences Fund III, L.P.; Bain Capital Life Sciences III General Partner, LLC; Bain Capital Life Sciences Investors, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":56224.0,"shares_display":"56,224","price_per_share":30.05,"price_display":"30.05","price_state":"stated","total_value":1689531.2,"total_display":"1,689,531.20","shares_owned_after":8448158.0,"shares_owned_after_display":"8,448,158","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-30","filed_date":"2026-04-30","scope":"insider"},{"id":6017262,"accession":"0001193125-26-198593","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-198593","line_url":"/filing/0001193125-26-198593#line-2","is_derivative":false,"issuer_cik":"0001464521","issuer_name":"Heartflow, Inc.","issuer_ticker":"HTFL","issuer_name_source":null,"issuer_url":"/issuer/0001464521","owner_cik":null,"owner_name":"BCLS Fund III Investments GP, LLC; BCLS Fund III Investments, LP; Bain Capital Life Sciences Fund III, L.P.; Bain Capital Life Sciences III General Partner, LLC; Bain Capital Life Sciences Investors, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":797133.0,"shares_display":"797,133","price_per_share":29.37,"price_display":"29.37","price_state":"stated","total_value":23411796.21,"total_display":"23,411,796.21","shares_owned_after":9396915.0,"shares_owned_after_display":"9,396,915","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-29","filed_date":"2026-04-30","scope":"insider"},{"id":6017260,"accession":"0001193125-26-198593","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-198593","line_url":"/filing/0001193125-26-198593#line-1","is_derivative":false,"issuer_cik":"0001464521","issuer_name":"Heartflow, Inc.","issuer_ticker":"HTFL","issuer_name_source":null,"issuer_url":"/issuer/0001464521","owner_cik":null,"owner_name":"BCLS Fund III Investments GP, LLC; BCLS Fund III Investments, LP; Bain Capital Life Sciences Fund III, L.P.; Bain Capital Life Sciences III General Partner, LLC; Bain Capital Life Sciences Investors, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":254110.0,"shares_display":"254,110","price_per_share":30.51,"price_display":"30.51","price_state":"stated","total_value":7752896.1,"total_display":"7,752,896.10","shares_owned_after":10194048.0,"shares_owned_after_display":"10,194,048","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-28","filed_date":"2026-04-30","scope":"insider"},{"id":5894265,"accession":"0001193125-26-164389","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-164389","line_url":"/filing/0001193125-26-164389#line-3","is_derivative":false,"issuer_cik":"0001703031","issuer_name":"Kailera Therapeutics, Inc.","issuer_ticker":"KLRA","issuer_name_source":null,"issuer_url":"/issuer/0001703031","owner_cik":null,"owner_name":"BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P.; Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1562500.0,"shares_display":"1,562,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":25000000.0,"total_display":"25,000,000.00","shares_owned_after":22583268.0,"shares_owned_after_display":"22,583,268","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-20","filed_date":"2026-04-20","scope":"insider"},{"id":5929487,"accession":"0001193125-26-041349","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-041349","line_url":"/filing/0001193125-26-041349#line-1","is_derivative":false,"issuer_cik":"0001464521","issuer_name":"Heartflow, Inc.","issuer_ticker":"HTFL","issuer_name_source":null,"issuer_url":"/issuer/0001464521","owner_cik":null,"owner_name":"BCLS Fund III Investments GP, LLC; BCLS Fund III Investments, LP; Bain Capital Life Sciences Fund III, L.P.; Bain Capital Life Sciences III General Partner, LLC; Bain Capital Life Sciences Investors, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000000.0,"shares_display":"2,000,000","price_per_share":28.05,"price_display":"28.05","price_state":"stated","total_value":56100000.0,"total_display":"56,100,000.00","shares_owned_after":10448158.0,"shares_owned_after_display":"10,448,158","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-04","filed_date":"2026-02-06","scope":"insider"},{"id":4376092,"accession":"0000950170-25-025011","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-025011","line_url":"/filing/0000950170-25-025011#line-1","is_derivative":false,"issuer_cik":"0001702921","issuer_name":"Solid Biosciences Inc.","issuer_ticker":"SLDB","issuer_name_source":null,"issuer_url":"/issuer/0001702921","owner_cik":null,"owner_name":"BCIP Life Sciences Associates, LP; BCLS II Equity Opportunities GP, LLC; BCLS II Equity Opportunities, LP; BCLS II Investco (GP), LLC; BCLS II Investco, LP; BCLS SB Investco, LP; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors II, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Partners, LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":4.03,"price_display":"4.03","price_state":"stated","total_value":4030000.0,"total_display":"4,030,000.00","shares_owned_after":5034582.0,"shares_owned_after_display":"5,034,582","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-02-19","filed_date":"2025-02-21","scope":"insider"},{"id":4581496,"accession":"0000950170-25-004870","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-004870","line_url":"/filing/0000950170-25-004870#line-1","is_derivative":false,"issuer_cik":"0001703031","issuer_name":"Olema Pharmaceuticals, Inc.","issuer_ticker":"OLMA","issuer_name_source":null,"issuer_url":"/issuer/0001703031","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Opportunities IV GP, LLC; Bain Capital Life Sciences Opportunities IV, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":5.7579,"price_display":"5.76","price_state":"stated","total_value":1727370.0,"total_display":"1,727,370.00","shares_owned_after":7800000.0,"shares_owned_after_display":"7,800,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-01-08","filed_date":"2025-01-13","scope":"insider"},{"id":2203450,"accession":"0000950170-24-015358","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-015358","line_url":"/filing/0000950170-24-015358#line-2","is_derivative":false,"issuer_cik":"0001703031","issuer_name":"Kyverna Therapeutics, Inc.","issuer_ticker":"KYTX","issuer_name_source":null,"issuer_url":"/issuer/0001703031","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund III, L.P.; Bain Capital Life Sciences III General Partner, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Opportunities III GP, LLC; Bain Capital Life Sciences Opportunities III, LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":450000.0,"shares_display":"450,000","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":9900000.0,"total_display":"9,900,000.00","shares_owned_after":3163868.0,"shares_owned_after_display":"3,163,868","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-12","filed_date":"2024-02-14","scope":"insider"},{"id":8135665,"accession":"0000899243-23-014139","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-014139","line_url":"/filing/0000899243-23-014139#line-1","is_derivative":false,"issuer_cik":"0001528115","issuer_name":"Annexon, Inc.","issuer_ticker":"ANNX","issuer_name_source":null,"issuer_url":"/issuer/0001528115","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":2.1324,"price_display":"2.13","price_state":"stated","total_value":639720.0,"total_display":"639,720.00","shares_owned_after":5701926.0,"shares_owned_after_display":"5,701,926","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-25","filed_date":"2023-05-30","scope":"insider"},{"id":5133830,"accession":"0000899243-21-047829","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-047829","line_url":"/filing/0000899243-21-047829#line-4","is_derivative":false,"issuer_cik":"0001702921","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001702921","owner_cik":null,"owner_name":"BCIP Life Sciences Associates, LP; BCLS II Investco, LP; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Investors II, LLC; BCLS II Investo (GP), LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21812.0,"shares_display":"21,812","price_per_share":9.5619,"price_display":"9.56","price_state":"stated","total_value":208564.1628,"total_display":"208,564.16","shares_owned_after":2802225.0,"shares_owned_after_display":"2,802,225","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-12-10","filed_date":"2021-12-10","scope":"insider"},{"id":5133825,"accession":"0000899243-21-047829","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-047829","line_url":"/filing/0000899243-21-047829#line-3","is_derivative":false,"issuer_cik":"0001702921","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001702921","owner_cik":null,"owner_name":"BCIP Life Sciences Associates, LP; BCLS II Investco, LP; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Investors II, LLC; BCLS II Investo (GP), LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3188.0,"shares_display":"3,188","price_per_share":10.2378,"price_display":"10.24","price_state":"stated","total_value":32638.1064,"total_display":"32,638.11","shares_owned_after":2805413.0,"shares_owned_after_display":"2,805,413","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-12-10","filed_date":"2021-12-10","scope":"insider"},{"id":5133819,"accession":"0000899243-21-047829","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-047829","line_url":"/filing/0000899243-21-047829#line-2","is_derivative":false,"issuer_cik":"0001702921","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001702921","owner_cik":null,"owner_name":"BCIP Life Sciences Associates, LP; BCLS II Investco, LP; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Investors II, LLC; BCLS II Investo (GP), LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4011.0,"shares_display":"4,011","price_per_share":9.8442,"price_display":"9.84","price_state":"stated","total_value":39485.0862,"total_display":"39,485.09","shares_owned_after":2780413.0,"shares_owned_after_display":"2,780,413","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-12-09","filed_date":"2021-12-10","scope":"insider"},{"id":5133813,"accession":"0000899243-21-047829","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-047829","line_url":"/filing/0000899243-21-047829#line-1","is_derivative":false,"issuer_cik":"0001702921","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001702921","owner_cik":null,"owner_name":"BCIP Life Sciences Associates, LP; BCLS II Investco, LP; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Investors II, LLC; BCLS II Investo (GP), LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13458.0,"shares_display":"13,458","price_per_share":9.6206,"price_display":"9.62","price_state":"stated","total_value":129474.0348,"total_display":"129,474.03","shares_owned_after":2776402.0,"shares_owned_after_display":"2,776,402","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-12-08","filed_date":"2021-12-10","scope":"insider"},{"id":4929726,"accession":"0000899243-21-032893","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-032893","line_url":"/filing/0000899243-21-032893#line-1","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"SpringWorks Therapeutics, Inc.","issuer_ticker":"SWTX","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"Koppel Adam; Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Investors, LLC; BC SW, LP","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000000.0,"shares_display":"1,000,000","price_per_share":70.25,"price_display":"70.25","price_state":"stated","total_value":70250000.0,"total_display":"70,250,000.00","shares_owned_after":4831307.0,"shares_owned_after_display":"4,831,307","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-10","filed_date":"2021-08-12","scope":"insider"},{"id":4305949,"accession":"0000899243-21-029222","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-029222","line_url":"/filing/0000899243-21-029222#line-3","is_derivative":false,"issuer_cik":"0001380106","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001380106","owner_cik":null,"owner_name":"Koppel Adam; Bain Capital Life Sciences Fund, L.P.; Schwartz Jeffrey Lawrence; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Partners, LP; Bain Capital Life Sciences Investors, LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":2000000.0,"total_display":"2,000,000.00","shares_owned_after":8434560.0,"shares_owned_after_display":"8,434,560","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-19","filed_date":"2021-07-21","scope":"insider"},{"id":4707870,"accession":"0000899243-21-011153","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-011153","line_url":"/filing/0000899243-21-011153#line-1","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"SpringWorks Therapeutics, Inc.","issuer_ticker":"SWTX","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"Koppel Adam; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence; BC SW, LP","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1450000.0,"shares_display":"1,450,000","price_per_share":71.5,"price_display":"71.50","price_state":"stated","total_value":103675000.0,"total_display":"103,675,000.00","shares_owned_after":5831307.0,"shares_owned_after_display":"5,831,307","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-09","filed_date":"2021-03-11","scope":"insider"},{"id":2419250,"accession":"0000899243-20-029321","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-029321","line_url":"/filing/0000899243-20-029321#line-1","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Aptinyx Inc.","issuer_ticker":"APTX","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"Koppel Adam; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Partners, LP; Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Investors, LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3333333.0,"shares_display":"3,333,333","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":9999999.0,"total_display":"9,999,999.00","shares_owned_after":8891758.0,"shares_owned_after_display":"8,891,758","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-26","filed_date":"2020-10-27","scope":"insider"},{"id":3279923,"accession":"0000899243-20-020554","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-020554","line_url":"/filing/0000899243-20-020554#line-3","is_derivative":false,"issuer_cik":"0001528115","issuer_name":"Annexon, Inc.","issuer_ticker":"ANNX","issuer_name_source":null,"issuer_url":"/issuer/0001528115","owner_cik":null,"owner_name":"Schwartz Jeffrey Lawrence; Koppel Adam; Bain Capital Life Sciences Partners, LP; Bain Capital Life Sciences Investors, LLC; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Fund, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":6800000.0,"total_display":"6,800,000.00","shares_owned_after":3241628.0,"shares_owned_after_display":"3,241,628","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-28","filed_date":"2020-07-28","scope":"insider"},{"id":2592132,"accession":"0000899243-20-003487","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-003487","line_url":"/filing/0000899243-20-003487#line-3","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"BCIP Life Sciences Associates, LP; Koppel Adam; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Partners, LP; Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Fund, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":294117.0,"shares_display":"294,117","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":4999989.0,"total_display":"4,999,989.00","shares_owned_after":3979292.0,"shares_owned_after_display":"3,979,292","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-04","filed_date":"2020-02-06","scope":"insider"},{"id":7775873,"accession":"0000899243-19-027786","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-027786","line_url":"/filing/0000899243-19-027786#line-1","is_derivative":false,"issuer_cik":"0001399529","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001399529","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Partners, LP; Koppel Adam; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Investors, LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1750000.0,"shares_display":"1,750,000","price_per_share":22.03,"price_display":"22.03","price_state":"stated","total_value":38552500.0,"total_display":"38,552,500.00","shares_owned_after":5580237.0,"shares_owned_after_display":"5,580,237","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-19","filed_date":"2019-11-21","scope":"insider"},{"id":7858007,"accession":"0000899243-19-023936","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-023936","line_url":"/filing/0000899243-19-023936#line-3","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"SpringWorks Therapeutics, Inc.","issuer_ticker":"SWTX","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"Schwartz Jeffrey Lawrence; Koppel Adam; Bain Capital Life Sciences Investors, LLC; BC SW, LP","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":2700000.0,"total_display":"2,700,000.00","shares_owned_after":7281307.0,"shares_owned_after_display":"7,281,307","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-17","filed_date":"2019-09-19","scope":"insider"},{"id":7830833,"accession":"0000899243-19-015281","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-015281","line_url":"/filing/0000899243-19-015281#line-1","is_derivative":false,"issuer_cik":"0001399529","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001399529","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Partners, LP; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence; Koppel Adam","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1600000.0,"shares_display":"1,600,000","price_per_share":12.5,"price_display":"12.50","price_state":"stated","total_value":20000000.0,"total_display":"20,000,000.00","shares_owned_after":7330237.0,"shares_owned_after_display":"7,330,237","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-29","filed_date":"2019-05-31","scope":"insider"},{"id":6717398,"accession":"0000899243-18-020659","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-020659","line_url":"/filing/0000899243-18-020659#line-2","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Fund, L.P.; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Partners, LP; Bain Capital Life Sciences Investors, LLC; Koppel Adam","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":7500000.0,"total_display":"7,500,000.00","shares_owned_after":2838968.0,"shares_owned_after_display":"2,838,968","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-07-24","filed_date":"2018-07-26","scope":"insider"},{"id":4217697,"accession":"0000899243-17-029256","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-17-029256","line_url":"/filing/0000899243-17-029256#line-5","is_derivative":false,"issuer_cik":"0001267813","issuer_name":"MARINUS PHARMACEUTICALS INC","issuer_ticker":"MRNS","issuer_name_source":null,"issuer_url":"/issuer/0001267813","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP; Koppel Adam; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":94771.0,"shares_display":"94,771","price_per_share":7.6209,"price_display":"7.62","price_state":"stated","total_value":722240.3139,"total_display":"722,240.31","shares_owned_after":4032682.0,"shares_owned_after_display":"4,032,682","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-19","filed_date":"2017-12-19","scope":"insider"},{"id":4217692,"accession":"0000899243-17-029256","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-17-029256","line_url":"/filing/0000899243-17-029256#line-4","is_derivative":false,"issuer_cik":"0001267813","issuer_name":"MARINUS PHARMACEUTICALS INC","issuer_ticker":"MRNS","issuer_name_source":null,"issuer_url":"/issuer/0001267813","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP; Koppel Adam; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55229.0,"shares_display":"55,229","price_per_share":7.1055,"price_display":"7.11","price_state":"stated","total_value":392429.6595,"total_display":"392,429.66","shares_owned_after":3977453.0,"shares_owned_after_display":"3,977,453","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-19","filed_date":"2017-12-19","scope":"insider"},{"id":4352432,"accession":"0000899243-17-029183","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-17-029183","line_url":"/filing/0000899243-17-029183#line-3","is_derivative":false,"issuer_cik":"0001399529","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001399529","owner_cik":null,"owner_name":"Koppel Adam; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP; Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Investors, LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":285000.0,"shares_display":"285,000","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":1995000.0,"total_display":"1,995,000.00","shares_owned_after":285000.0,"shares_owned_after_display":"285,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-18","filed_date":"2017-12-19","scope":"insider"},{"id":4217689,"accession":"0000899243-17-029256","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-17-029256","line_url":"/filing/0000899243-17-029256#line-3","is_derivative":false,"issuer_cik":"0001267813","issuer_name":"MARINUS PHARMACEUTICALS INC","issuer_ticker":"MRNS","issuer_name_source":null,"issuer_url":"/issuer/0001267813","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP; Koppel Adam; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300000.0,"shares_display":"300,000","price_per_share":7.5048,"price_display":"7.50","price_state":"stated","total_value":2251440.0,"total_display":"2,251,440.00","shares_owned_after":4127453.0,"shares_owned_after_display":"4,127,453","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-18","filed_date":"2017-12-19","scope":"insider"},{"id":4217685,"accession":"0000899243-17-029256","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-17-029256","line_url":"/filing/0000899243-17-029256#line-2","is_derivative":false,"issuer_cik":"0001267813","issuer_name":"MARINUS PHARMACEUTICALS INC","issuer_ticker":"MRNS","issuer_name_source":null,"issuer_url":"/issuer/0001267813","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP; Koppel Adam; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":719665.0,"shares_display":"719,665","price_per_share":8.0179,"price_display":"8.02","price_state":"stated","total_value":5770202.0035,"total_display":"5,770,202.00","shares_owned_after":4530335.0,"shares_owned_after_display":"4,530,335","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-15","filed_date":"2017-12-19","scope":"insider"},{"id":4217682,"accession":"0000899243-17-029256","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-17-029256","line_url":"/filing/0000899243-17-029256#line-1","is_derivative":false,"issuer_cik":"0001267813","issuer_name":"MARINUS PHARMACEUTICALS INC","issuer_ticker":"MRNS","issuer_name_source":null,"issuer_url":"/issuer/0001267813","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP; Koppel Adam; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":102882.0,"shares_display":"102,882","price_per_share":8.636,"price_display":"8.64","price_state":"stated","total_value":888488.952,"total_display":"888,488.95","shares_owned_after":4427453.0,"shares_owned_after_display":"4,427,453","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-15","filed_date":"2017-12-19","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001464521","name":"Heartflow, Inc.","url":"/issuer/0001464521","role":"Ten percent owner","n_filings":2,"first_seen":"2026-02-06","last_seen":"2026-04-30"},{"type":"issuer","type_label":"ISSUER","cik":"0002096997","name":"Kailera Therapeutics, Inc.","url":"/issuer/0002096997","role":"Ten percent owner","n_filings":1,"first_seen":"2026-04-20","last_seen":"2026-04-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001707502","name":"Solid Biosciences Inc.","url":"/issuer/0001707502","role":"Ten percent owner","n_filings":1,"first_seen":"2025-02-21","last_seen":"2025-02-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001750284","name":"Olema Pharmaceuticals, Inc.","url":"/issuer/0001750284","role":"Ten percent owner","n_filings":1,"first_seen":"2025-01-13","last_seen":"2025-01-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001994702","name":"Kyverna Therapeutics, Inc.","url":"/issuer/0001994702","role":"Ten percent owner","n_filings":1,"first_seen":"2024-02-14","last_seen":"2024-02-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001528115","name":"Annexon, Inc.","url":"/issuer/0001528115","role":"Ten percent owner","n_filings":2,"first_seen":"2020-07-28","last_seen":"2023-05-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001840233","name":"Xilio Therapeutics, Inc.","url":"/issuer/0001840233","role":"Ten percent owner","n_filings":1,"first_seen":"2021-12-10","last_seen":"2021-12-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001773427","name":"SpringWorks Therapeutics, Inc.","url":"/issuer/0001773427","role":"Ten percent owner","n_filings":3,"first_seen":"2019-09-19","last_seen":"2021-08-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001380106","name":"RAPID MICRO BIOSYSTEMS, INC.","url":"/issuer/0001380106","role":"Ten percent owner","n_filings":1,"first_seen":"2021-07-21","last_seen":"2021-07-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001674365","name":"Aptinyx Inc.","url":"/issuer/0001674365","role":"Ten percent owner","n_filings":1,"first_seen":"2020-10-27","last_seen":"2020-10-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001787306","name":"Arcutis Biotherapeutics, Inc.","url":"/issuer/0001787306","role":"Ten percent owner","n_filings":1,"first_seen":"2020-02-06","last_seen":"2020-02-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001399529","name":"Dicerna Pharmaceuticals Inc","url":"/issuer/0001399529","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2017-12-19","last_seen":"2019-11-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001737953","name":"Replimune Group, Inc.","url":"/issuer/0001737953","role":"Ten percent owner","n_filings":1,"first_seen":"2018-07-26","last_seen":"2018-07-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001267813","name":"MARINUS PHARMACEUTICALS INC","url":"/issuer/0001267813","role":"Ten percent owner","n_filings":1,"first_seen":"2017-12-19","last_seen":"2017-12-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001703031","retrieved_at":"2026-08-21T02:00:22+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-19","last_ingest":"2026-08-20T05:22:56.381658+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}